Background The host adaptive immune response helps determine which cervical HPV
infections persist and progress to precancer and cancer, and systematic characterisation of …

Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast
cancers and is characterized by a lack of immunohistochemical expression of estrogen …

Aberrant signal transducer and activator of transcription 3 (STAT3) signaling promotes the
initiation and progression of cancer in humans by either inhibiting apoptosis or inducing cell …

Simple Summary The aim of this review is to assess the available literature of the
pharmacological treatment of patients with metastatic, recurrent or persistent cervical cancer …

Cervical cancer is a public health problem of extensive clinical importance. Excision repair
cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical …

Objective: Genetic polymorphisms can influence the chemotherapeutic response; however,
previous studies have produced conflicting results, and have failed to identify the most …

The deoxyribonucleic acid (DNA) repair gene encoding the excision-repair cross-
complementation group 1 (ERCC1) protein is known to predict the response to platinum …

Src homology phosphotyrosine phosphatase 2 (Shp2) has been found to be overexpressed
in cervical cancer tissues. However, the influence of Shp2 on the biological behavior and …

The expression of Notch1 plays an important role in the occurrence and development of
various tumors. Previous studies have shown that Notch1 plays a negative regulatory role in …

Background Trastuzumab emtansine (T-DM1) has been approved worldwide for treating
metastatic breast cancer (mBC) in patients who have received first-line therapy, shown …